Combination-Only Approvals as a Barrier to Affordable HIV Care

JAMA. 2026 Jan 6;335(1):19-20. doi: 10.1001/jama.2025.21935.

S Sean Tu^{1

2}, Timothy Bonis³, Michael S Sinha⁴, David H Slade⁵

¹ University of Alabama School of Law, Tuscaloosa.
² Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
³ Dartmouth College, Hanover, New Hampshire.
⁴ Center for Health Law Studies, Saint Louis University School of Law, St Louis, Missouri.
⁵ Department of Infectious Diseases, Loyola University Medical Center and Hines VA Medical Center, Hines, Illinois.

No abstract available

Plain language summary

This Viewpoint discusses the barrier that combination-only antiretroviral therapy drugs have been to access of affordable HIV care.